ACHC Acadia Healthcare (ACHC) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-specialty outpatient facilities, nec · CIK 0001520697
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
169
13F, latest reported quarter
Acadia Healthcare insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Acadia Healthcare Company, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.8% of the 46,074 shares held after it.
- 1 other insider sold within 30 days.
- 169 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Miquelon Wade D sold about $188.1K of ACHC on Mar 5, 2024; 1 other insider sold within 30 days and 169 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.3% of the 26,851 shares held after it.
- 1 other insider sold within 30 days.
- 169 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Gregg Vicky B sold about $213.9K of ACHC on Mar 4, 2024; 1 other insider sold within 30 days and 169 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 12, 2023.
- The trade is 5.2% of the 675,833 shares held after it.
- 1 other insider sold within 30 days.
- 169 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director OSTEEN DEBRA K sold about $2.7M of ACHC on Dec 13, 2023, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 169 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 8, 2023.
- The trade is 1.1% of the 710,833 shares held after it.
- 1 other insider sold within 30 days.
- 169 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director OSTEEN DEBRA K sold about $609.8K of ACHC on Dec 12, 2023; 1 other insider sold within 30 days and 169 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 10, 2023.
- The trade is 32.5% of the 84,630 shares held after it.
- 1 other insider sold within 30 days.
- 169 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP of Operations Hollinsworth John S. sold about $2.0M of ACHC on Nov 14, 2023, the largest insider sale at the company since 2022; 1 other insider sold within 30 days and 169 funds added in the latest 13F quarter.19 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
169 funds bought in last quarter
more than 72% of Healthcare Services
Revenue
+5.0% year over year
below 69% of Healthcare Services
Margin
-33.3% net margin
below 81% of Healthcare Services
Buybacks
$50.0M repurchased, FY to 2025-12-31
below 52% of Healthcare Services
Short interest
24.9% of the float short (float per yahoo 2026-10-26) · 13.9 days to cover · settled 2026-09-30
more than 99% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ACHC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+33.6%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ACHC: institutional holders (13F)
13F holdings, latest reported quarter
14,957,168 sh
$441.7M
5,726,246 sh
$169.1M
5,369,461 sh
$158.6M
5,015,727 sh
$148.1M
4,762,635 sh
$140.6M
Congress trades in ACHC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ACHC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ACHC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.8M position · as of 2026-06-30
2.0%
Invesco S&P Smallcap 600 Pure Value ETF
$5.5M position · as of 2026-07-31
1.9%
S&P SmallCap 600 Pure Value Fund
$211.0K position · as of 2026-06-30
1.8%
Brown Advisory Small-Cap Fundamental Value Fund
$17.4M position · as of 2026-06-30
1.4%
AMG GW&K Small Cap Value Fund
$3.2M position · as of 2026-06-30
1.4%
AMG Frontier Small Cap Growth Fund
$1.2M position · as of 2026-07-31
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 169 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ACHC financials
Revenue growth
+5.0%
XBRL, annual
Net margin
-33.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.4B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM ACHC
| FY Dec 2025 | $3.3B |
| FY Dec 2024 | $3.2B |
| FY Dec 2023 | $2.9B |
| FY Dec 2022 | $2.6B |
| FY Dec 2021 | $2.3B |
| Mar 2026 | $828.8M |
| Dec 2025 | $821.5M |
| Sep 2025 | $851.6M |
| Jun 2025 | $869.2M |
| Mar 2025 | $770.5M |
| Dec 2024 | $774.2M |
| Sep 2024 | $815.6M |
| Jun 2024 | $796.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-32.8%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM ACHC
| FY Dec 2025 | -33.3% |
| FY Dec 2024 | +8.1% |
| FY Dec 2023 | -0.7% |
| FY Dec 2022 | +10.5% |
| FY Dec 2021 | +8.2% |
| Mar 2026 | +0.5% |
| Dec 2025 | -143.3% |
| Sep 2025 | +4.3% |
| Jun 2025 | +3.5% |
| Mar 2025 | +1.1% |
| Dec 2024 | +4.2% |
| Sep 2024 | +8.4% |
| Jun 2024 | +9.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$291.8M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM ACHC
| FY Dec 2025 | -$439.9M |
| FY Dec 2024 | -$560.7M |
| FY Dec 2023 | $38.2M |
| FY Dec 2022 | $84.4M |
| FY Dec 2021 | $129.7M |
| Mar 2026 | -$15.0M |
| Dec 2025 | -$179.5M |
| Sep 2025 | -$63.0M |
| Jun 2025 | -$34.2M |
| Mar 2025 | -$163.2M |
| Dec 2024 | -$86.8M |
| Sep 2024 | -$27.1M |
| Jun 2024 | $16.9M |
At each fiscal year end
Single quarter
Debt to equity
1.29x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity ACHC
| FY Dec 2025 | 1.28x |
| FY Dec 2024 | 0.64x |
| FY Dec 2023 | 0.49x |
| FY Dec 2022 | 0.49x |
| FY Dec 2021 | 0.59x |
| Mar 2026 | 1.29x |
| Dec 2025 | 1.28x |
| Sep 2025 | 0.74x |
| Jun 2025 | 0.74x |
| Mar 2025 | 0.72x |
| Dec 2024 | 0.64x |
| Sep 2024 | 0.62x |
| Jun 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.07x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt ACHC
| FY Dec 2025 | 0.05x |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | 0.34x |
| FY Dec 2022 | 0.27x |
| FY Dec 2021 | 0.25x |
| Mar 2026 | 0.07x |
| Dec 2025 | 0.05x |
| Sep 2025 | 0.15x |
| Jun 2025 | 0.19x |
| Mar 2025 | 0.21x |
| Dec 2024 | 0.07x |
| Sep 2024 | 0.07x |
| Jun 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-44.3%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity ACHC
| FY Dec 2025 | -43.9% |
| FY Dec 2024 | +8.7% |
| FY Dec 2023 | -0.8% |
| FY Dec 2022 | +10.2% |
| FY Dec 2021 | +8.6% |
| Mar 2026 | -44.3% |
| Dec 2025 | -43.9% |
| Sep 2025 | +3.5% |
| Jun 2025 | +4.6% |
| Mar 2025 | +6.4% |
| Dec 2024 | +8.7% |
| Sep 2024 | +9.8% |
| Jun 2024 | -0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-18.9%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets ACHC
| FY Dec 2025 | -19.2% |
| FY Dec 2024 | +4.5% |
| FY Dec 2023 | -0.4% |
| FY Dec 2022 | +5.6% |
| FY Dec 2021 | +3.4% |
| Mar 2026 | -18.9% |
| Dec 2025 | -19.2% |
| Sep 2025 | +1.7% |
| Jun 2025 | +2.3% |
| Mar 2025 | +3.2% |
| Dec 2024 | +4.5% |
| Sep 2024 | +5.0% |
| Jun 2024 | -0.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ACHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | +9.4% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +11.1% |
| FY Dec 2021 | +12.8% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +9.3% |
| Jun 2025 | +8.5% |
| Mar 2025 | +8.7% |
| Dec 2024 | +9.4% |
| Sep 2024 | +9.5% |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+10.9%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed ACHC
| FY Dec 2025 | +11.2% |
| FY Dec 2024 | +11.8% |
| FY Dec 2023 | +12.8% |
| FY Dec 2022 | +13.0% |
| FY Dec 2021 | +12.2% |
| Mar 2026 | +10.9% |
| Dec 2025 | +11.2% |
| Sep 2025 | +10.4% |
| Jun 2025 | +10.7% |
| Mar 2025 | +10.9% |
| Dec 2024 | +11.8% |
| Sep 2024 | +12.0% |
| Jun 2024 | +11.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ACHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | 14.26x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 27.44x |
| FY Dec 2021 | 28.90x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 20.98x |
| Jun 2025 | 14.93x |
| Mar 2025 | 14.86x |
| Dec 2024 | 14.26x |
| Sep 2024 | 20.79x |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.3B
market value at close 2026-10-26 on 2026-02-25 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value ACHC
| FY Dec 2025 | $3.7B |
| FY Dec 2024 | $5.6B |
| FY Dec 2023 | $8.4B |
| FY Dec 2022 | $8.8B |
| FY Dec 2021 | $6.8B |
| Mar 2026 | $4.5B |
| Dec 2025 | $3.7B |
| Sep 2025 | $4.5B |
| Jun 2025 | $4.2B |
| Mar 2025 | $4.9B |
| Dec 2024 | $5.6B |
| Sep 2024 | $7.7B |
| Jun 2024 | $8.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-10.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield ACHC
| FY Dec 2025 | -33.6% |
| FY Dec 2024 | -15.2% |
| FY Dec 2023 | +0.5% |
| FY Dec 2022 | +1.1% |
| FY Dec 2021 | +2.4% |
| Mar 2026 | -13.5% |
| Dec 2025 | -33.6% |
| Sep 2025 | -15.2% |
| Jun 2025 | -14.9% |
| Mar 2025 | -9.2% |
| Dec 2024 | -15.2% |
| Sep 2024 | -8.4% |
| Jun 2024 | -7.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ACHC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.64x |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.3B | $3.2B | $2.9B | $2.6B |
| Net income | -$1.1B | $255.6M | -$21.7M | $273.1M |
| EPS (diluted) | -12.16 | 2.78 | -0.24 | 2.98 |
| Operating cash flow | $131.9M | $129.7M | $462.3M | $380.6M |
| Cash | $133.2M | $76.3M | $100.1M | $97.6M |
| Long-term debt | $2.5B | $1.9B | $1.3B | $1.4B |
| Buybacks | $50.0M | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
ACHC Stock Sonar score 5/7 axes
Find similar shapesCompareACHC ranks highest on institutional and government (61st percentile) and profitability (44th), and lowest on risk and compliance (31st), among Healthcare Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
